Volume 4.42 | Oct 25

Mammary Cell News 4.42 October 25, 2012
Mammary Cell News
     In this issue: Publications | Reviews | Science NewsIndustry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
The Requirement for Cyclin D Function in Tumor Maintenance
To test the efficacy of targeting D-cyclins in cancer treatment, researchers engineered mouse strains that allow acute and global ablation of individual D-cyclins in a living animal. Ubiquitous shutdown of cyclin D1 or inhibition of cyclin D-associated kinase activity in mice bearing ErbB2-driven mammary carcinomas triggered tumor cell senescence, without compromising the animals’ health. [Cell Canc Cell] Abstract | Press Release

Don't Lose Sleep Over Mouse Mammary Tissue Dissociation (New Enzymes: Learn More)
PUBLICATIONS (Ranked by impact factor of the journal)


Elf5 Inhibits the Epithelial-Mesenchymal Transition in Mammary Gland Development and Breast Cancer Metastasis by Transcriptionally Repressing Snail2
Scientists showed that the transcription factor Elf5, a key regulator of mammary gland alveologenesis, controls epithelial-mesenchymal transition in both mammary gland development and metastasis. [Nat Cell Biol] Abstract | Press Release

Estrogen Receptor Prevents p53-Dependent Apoptosis in Breast Cancer
Using genome-wide approaches, investigators addressed the mechanism by which the estrogen receptor (ER) antagonizes the proapoptotic function of p53. Both ER agonists such as estradiol and the selective ER modulator tamoxifen promote p53 antagonism. [Proc Natl Sci USA] Abstract

Control of Breast Cancer Growth and Initiation by the Stem Cell-Associated Transcription Factor TCF3
Researchers found that TCF3 is highly expressed in poorly differentiated human breast cancers, preferentially of the basal-like subtype. This suggested that TCF3 is involved in the regulation of breast cancer cell differentiation state and tumorigenicity. [Cancer Res] Abstract

Histone Deacetylase Inhibitors Stimulate Dedifferentiation of Human Breast Cancer Cells Through WNT/β-Catenin Signaling
Two highly aggressive breast cancer cell lines were sorted based on aldehyde dehydrogenase (ALDH) activity and subsequently ALDH-negative and ALDH-positive cells were treated with one of two known histone deacetylase inhibitors, valproic acid or suberoylanilide hydroxamic acid. [Stem Cells] Abstract

Fibroblast Growth Factor Receptor Signaling Is Essential for Normal Mammary Gland Development and Stem Cell Function
Using a conditional deletion strategy, researchers investigated the consequences of fibroblast growth factor receptor-1 (FGFR1) deletion alone, and then the simultaneous deletion of both FGFR1 and FGFR2 in the mammary epithelium. [Stem Cells] Abstract

Effectiveness and Molecular Interactions of the Clinically Active Mammalian Target of Rapamycin-1 Inhibitor Everolimus in Combination with Tamoxifen or Letrozole In Vitro and In Vivo
Breast cancer cell lines expressing aromatase and modeling endocrine-sensitive and human epidermal growth factor receptor 2 (HER2)-dependent de novo resistant disease and long-term estrogen-deprived MCF7 cells that had acquired resistance associated with HER2 overexpression, were treated in vitro and as subcutaneous xenografts with everolimus, in combination with tamoxifen or letrozole. [Breast Cancer Res]
Abstract | Full Article

Mitochondria Organelle Transplantation: Introduction of Normal Epithelial Mitochondria into Human Cancer Cells Inhibits Proliferation and Increases Drug Sensitivity
Investigators hypothesized that the introduction of normal mitochondria into cancer cells might restore mitochondrial function and inhibit cancer cell growth, and reverse chemoresistance. [Breast Cancer Res Treat] Abstract

STAT3-RANTES Autocrine Signaling Is Essential for Tamoxifen Resistance in Human Breast Cancer Cells
The acquisition of tamoxifen resistance is a major therapeutic problem in breast cancer. Scientists developed a tamoxifen-resistant MCF-7 cell line to elucidate the molecular mechanisms and factors associated with acquisition of such resistance. They demonstrated that phosphorylation of STAT3 at tyrosine 705 and RANTES expression are increased in response to tamoxifen in human breast cancer cells. [Mol Cancer Res] Abstract

Prognostic Impact of FOXP3 Expression in Triple-Negative Breast Cancer
Researchers investigated whether there were significant numbers of forkhead box protein 3 (FOXP3)-positive regulatory T cells (Tregs) in triple-negative breast cancer using immunohistochemistry, and whether the presence of FOXP3-positive Tregs was associated with other prognostic factors, such as stage or histologic grade. [Acta Oncol] Abstract


Patterns of Use and Short-Term Complications of Breast Brachytherapy in the National Medicare Population from 2008-2009
Investigators constructed a national sample of Medicare beneficiaries ages 66 to 94 years who underwent breast-conserving surgery from 2008 to 2009 and were treated with brachytherapy or whole-breast irradiation. They used hospital referral regions to assess national treatment variation and an instrumental variable analysis to compare complication rates between treatment groups, adjusting for patient and clinical characteristics. [J Clin Oncol] Abstract | Press Release

Hospital Recorded Morbidity and Breast Cancer Incidence: A Nationwide Population-Based Case-Control Study
Data on all Danish women aged 45 to 85 years, diagnosed with breast cancer between 1994 and 2008 and data on preceding morbidities were retrieved from nationwide medical registries. Odds ratios and 95% confidence intervals were estimated using conditional logistic regression associating the Charlson comorbidity score with incident breast cancer. [PLoS One] Full Article

50,000 scientists receive our newsletters. Do your colleagues? Click to share this newsletter now.

Characterization of Tumor Differentiation Factor (TDF) and Its Receptor (TDF-R)
The authors review the current advances on TDF, with particular focus on the structural investigation of its receptor and on its functional effects on breast and prostate cells. [Cell Mol Life Sci] Abstract

High Levels of Estradiol, Progesterone during Pregnancy Associated with Increased Risk for HR-Negative Breast Cancer
Increased concentrations of the pregnancy hormones estradiol and progesterone were associated with an increased risk for hormone receptor (HR)-negative breast cancer diagnosed before age 50. [Press release from the American Association for Cancer Research (AACR) discussing research presented at the 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research, Anaheim] Press Release 

Blood Hormone Levels Predicted Long-Term Breast Cancer Risk for Postmenopausal Women
Blood hormone tests predicted a woman’s risk for developing postmenopausal breast cancer for up to 20 years, according to data from the Nurses’ Health Study. [Press release from the American Association for Cancer Research (AACR) discussing research presented at the 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research, Anaheim] Press Release

Breast-Feeding Reduced Risk for ER/PR-Negative Breast Cancer
Breast-feeding reduced the risk for estrogen receptor (ER)-negative and progesterone receptor (PR)-negative breast cancer.  [Press release from the American Association for Cancer Research (AACR) discussing research presented at the 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research, Anaheim] Press Release


Cardinal Health Specialty Solutions, Blue Cross and Blue Shield of Louisiana Launch Quality Program for Cancer Treatment
Blue Cross and Cardinal Health Specialty Solutions will establish a committee composed of network oncologists in communities across Louisiana. The committee will identify evidence-based treatment regimens, or clinical pathways, for delivering patient care for breast, colon and lung cancers, among others. [Cardinal Health] Press Release

NIH-CRM Awards Cellular Dynamics up to $7 Million to Produce Human Induced Pluripotent Stem Cells and Differentiated Tissue Cells
The National Institutes of Health Center for Regenerative Medicine (NIH-CRM) has awarded Cellular Dynamics International, Inc. a contract to provide human induced pluripotent stem cell lines and terminally differentiated tissue cells from normal or specified patient populations. The contract is worth up to $7.0 million for the three year life of the agreement. [Cellular Dynamics, Inc.] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW 5th Breast Gynecological International Cancer Conference 2013 (BGICC)
January 17-18, 2013
Cairo, Egypt

our events page to see a complete list of events in the mammary cell community.


Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Product Quality Scientist (STEMCELL Technologies, Inc.)

Product Manager – Hematopoietic (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Assistant Professor – Breast Cancer Research (Johns Hopkins University)

Postdoctoral Position – Stem Cell/Cancer/Developmental Biology (Tufts University School of Medicine)

Postdoctoral Fellow – Gene Regulation in Breast Cancer/Stem Cell Biology (University of Cincinnati)

Associate Attending Breast Pathologist (Memorial Sloan-Kettering Cancer Center)

Postdoctoral Fellow – Breast Cancer Research (Mayo Clinic)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

Recruit Top Talent
: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us